drugset / Trial / NCT07098897
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy. The control group will be observed for up to 6months without administration of Telitacicept. This Single center, Randomized, Open Label, Comparative study will evaluate the effect and safety of and Standard treatment for 6months in IgA Nephropathy.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2025-05-25
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylprednisolone | Other / unclassified | 1 mg/kg | — |
| Comparator | Prednisolone | Other / unclassified | 1 mg/kg | — |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |